Summary & Overview
HCPCS J7601: Ensifentrine Inhalation Suspension, 3 mg Unit Dose
HCPCS Level II code J7601 designates a 3 mg unit dose of ensifentrine inhalation suspension, an FDA-approved, non-compounded product intended for administration via durable medical equipment (DME). This code captures the drug component of nebulized ensifentrine therapy when supplied as a unit dose for inhalation. Nationally, a distinct HCPCS Level II code for ensifentrine matters because it enables standardized billing, tracking of utilization, and clearer payer coverage determinations for a novel inhaled therapeutic delivered through DME.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service settings, plus what to expect from payer coverage considerations. The publication outlines benchmarks and reimbursement themes, highlights coding and billing implications tied to DME-administered inhalation drugs, and summarizes potential policy updates and payer coverage patterns relevant to ensifentrine. Data not available in the input will be noted where applicable. The focus is national and intended for clinicians, billers, revenue cycle professionals, and policy analysts seeking a practical reference for HCPCS Level II code J7601.
Billing Code Overview
HCPCS Level II code J7601 represents Ensifentrine, inhalation suspension, FDA approved final product, non-compounded, administered through DME, unit dose form, 3 mg. This entry describes a single unit dose of a nebulized inhalation suspension formulation of ensifentrine intended for delivery via durable medical equipment (DME).
-
Service Type: Drug administration (nebulized inhalation suspension) provided as a DME-administered unit dose.
-
Typical Site of Service: Care settings where durable medical equipment is used for inhalation therapy, including outpatient clinics, infusion or respiratory therapy suites, home with DME, and other ambulatory settings that support nebulized medication delivery.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old with chronic obstructive pulmonary disease (COPD) who presents for inhaled bronchodilator therapy optimization after persistent dyspnea and frequent exacerbations despite maintenance inhaled therapy. The patient receives a single-unit dose of J7601 (Ensifentrine, inhalation suspension, 3 mg, administered through durable medical equipment) during a clinic visit or at home with DME support. Clinical workflow: physician documents indication and medication order, DME provider prepares the device and confirms compatibility, trained clinician or respiratory therapist demonstrates device use and administers the J7601 unit dose if required, observes for immediate adverse effects for 15–30 minutes, documents administration in the medical record including lot number and route via DME, and schedules follow-up for symptom assessment and inhaler technique. Encounter sites commonly include outpatient pulmonary clinic, hospital outpatient infusion/respiratory therapy suite, or the patient’s home when DME services are authorized. Payers involved may include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare depending on coverage and benefit design.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default billing condition |